L. E. Shepherd

1.1k total citations
43 papers, 800 citations indexed

About

L. E. Shepherd is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, L. E. Shepherd has authored 43 papers receiving a total of 800 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 22 papers in Cancer Research and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in L. E. Shepherd's work include Breast Cancer Treatment Studies (21 papers), Cancer Treatment and Pharmacology (15 papers) and Estrogen and related hormone effects (15 papers). L. E. Shepherd is often cited by papers focused on Breast Cancer Treatment Studies (21 papers), Cancer Treatment and Pharmacology (15 papers) and Estrogen and related hormone effects (15 papers). L. E. Shepherd collaborates with scholars based in Canada, United States and Belgium. L. E. Shepherd's co-authors include J. N. Ingle, Dongsheng Tu, H. B. Muss, Michael Palmer, Kathleen I. Pritchard, Michael Crump, Joseph L. Pater, Nicholas J. Robert, Silvana Martino and Stephen Couban and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

L. E. Shepherd

40 papers receiving 774 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
L. E. Shepherd Canada	15	534	307	246	185	184	43	800
Akihiro Ohmoto Japan	14	418 0.8×	130 0.4×	70 0.3×	114 0.6×	99 0.5×	75	706
K.N. Price Switzerland	10	294 0.6×	256 0.8×	206 0.8×	51 0.3×	201 1.1×	19	597
Daria Arbogast United States	9	483 0.9×	79 0.3×	164 0.7×	70 0.4×	149 0.8×	9	1.2k
T Brown United States	14	293 0.5×	147 0.5×	186 0.8×	103 0.6×	123 0.7×	43	903
C.D.M. Griffith United Kingdom	16	465 0.9×	512 1.7×	255 1.0×	280 1.5×	208 1.1×	27	980
Luciano Canobbio Italy	19	512 1.0×	161 0.5×	43 0.2×	76 0.4×	190 1.0×	53	812
Virginia Cappagli Italy	18	308 0.6×	95 0.3×	195 0.8×	113 0.6×	149 0.8×	38	1.1k
Elham Khanafshar United States	21	377 0.7×	152 0.5×	330 1.3×	133 0.7×	160 0.9×	48	1.6k
H.T. Mouridsen Denmark	12	566 1.1×	273 0.9×	150 0.6×	119 0.6×	310 1.7×	33	787
Ömer Yerci Türkiye	16	281 0.5×	125 0.4×	45 0.2×	120 0.6×	168 0.9×	76	891

Countries citing papers authored by L. E. Shepherd

Since Specialization

Citations

This map shows the geographic impact of L. E. Shepherd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. E. Shepherd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. E. Shepherd more than expected).

Fields of papers citing papers by L. E. Shepherd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. E. Shepherd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. E. Shepherd. The network helps show where L. E. Shepherd may publish in the future.

Co-authorship network of co-authors of L. E. Shepherd

This figure shows the co-authorship network connecting the top 25 collaborators of L. E. Shepherd. A scholar is included among the top collaborators of L. E. Shepherd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. E. Shepherd. L. E. Shepherd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mahner, Sven�, Fabian Trillsch, Janice S. Kwon, et al.. (2025). Surgical approach, preoperative LEEP/conization and patterns of recurrence and death in low-risk cervical cancer – exploratory analysis from the CCTG CX.5/SHAPE trial. International Journal of Surgery. 111(11). 8099–8107.

Goss, Paul E., J. N. Ingle, Silvana Martino, et al.. (2012). Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Annals of Oncology. 24(2). 355–361. 60 indexed citations

Shepherd, L. E., Karen A. Gelmon, Barbara Walley, et al.. (2012). Abstract P1-13-01: A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: Results of the final relapse free survival analysis.. Cancer Research. 72(24_Supplement). P1–13. 3 indexed citations

Ingle, James N., Daniel J. Schaid, Taisei Mushiroda, et al.. (2009). A Genome-Wide Association Study in Patients Experiencing Musculoskeletal Adverse Events on Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer Entered on NCIC CTG Trial MA.27. A Pharmacogenetics Research Network-RIKEN Collaboration.. Cancer Research. 69(24_Supplement). 15–15. 2 indexed citations

Stearns, Vered, J. W. Chapman, X. Cynthia, et al.. (2009). Treatment-Emergent Symptoms and the Risk of Breast Cancer Recurrence in the NCIC CTG MA.27 Adjuvant Aromatase Inhibitor Trial.. Cancer Research. 69(24_Supplement). 14–14. 7 indexed citations

Munro, Alison F., Christine Desmedt, Janet Dunn, et al.. (2009). Duplication of Chromosome 17 CEP Predicts for Anthracycline Benefit: A Meta-Analysis of 4 Trials.. Cancer Research. 69(24_Supplement). 4030–4030. 2 indexed citations

Shepherd, L. E., et al.. (2008). Competing Causes of Death From a Randomized Trial of Extended Adjuvant Endocrine Therapy for Breast Cancer. JNCI Journal of the National Cancer Institute. 100(4). 252–260. 135 indexed citations

Ingle, J. N., Dongsheng Tu, Joseph L. Pater, et al.. (2008). Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Annals of Oncology. 19(5). 877–882. 46 indexed citations

Lipton, Allan, Judy‐Anne W. Chapman, Laurence M. Demers, et al.. (2008). Use of elevated bone turnover to predict bone metastasis. Journal of Clinical Oncology. 26(15_suppl). 591–591. 4 indexed citations

10.

Findlay, B., Katia Tonkin, Michael Crump, et al.. (2007). A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes. Annals of Oncology. 18(10). 1646–1651. 8 indexed citations

11.

Moy, Beverly, Dongsheng Tu, L. E. Shepherd, et al.. (2006). NCIC CTG MA.17: Tolerability of letrozole among ethnic minority women. Journal of Clinical Oncology. 24(18_suppl). 6018–6018. 1 indexed citations

12.

Moy, Beverly, Dongsheng Tu, Joseph L. Pater, et al.. (2006). Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer. Annals of Oncology. 17(11). 1637–1643. 26 indexed citations

13.

Tu, Dongping, et al.. (2006). NCIC CTG MA.17: Intent to treat analysis (ITT) of randomized patients after a median follow-up of 54 months. Journal of Clinical Oncology. 24(18_suppl). 549–549. 14 indexed citations

14.

Ackland, Stephen P., Michael Jones, Dongping Tu, et al.. (2005). A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. British Journal of Cancer. 93(11). 1236–1243. 41 indexed citations

15.

Luk, Cynthia T., et al.. (2005). Determinants of preferences for starting extended adjuvant letrozole (L) in postmenopausal women following five years of tamoxifen. Journal of Clinical Oncology. 23(16_suppl). 642–642. 1 indexed citations

16.

MacDonald, David, Mary Gospodarowicz, Woodrow Wells, et al.. (2005). Relapse Patterns and Subsequent Outcomes of Patients Treated on the NCIC CTG HD.6 (ECOG JHD06) Randomized Trial Evaluating ABVD Alone in Patients with Limited Stage Hodgkin Lymphoma (HL).. Blood. 106(11). 817–817. 3 indexed citations

17.

Goffin, John R., C. Savage, Dongsheng Tu, et al.. (2004). The difference between study recommendations, stated policy, and actual practice in a clinical trial. Annals of Oncology. 15(8). 1267–1273. 1 indexed citations

18.

Goss, Paul E., J. N. Ingle, Silvana Martino, et al.. (2004). Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. Journal of Clinical Oncology. 22(14_suppl). 847–847. 63 indexed citations

19.

Baetz, Tara, Andrew R. Belch, Stephen Couban, et al.. (2003). Gemcitabine, dexamethasone and cisplatin is an active andnon-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Annals of Oncology. 14(12). 1762–1767. 120 indexed citations

20.

Glück, Stefan, Michael Crump, MN Levine, et al.. (2001). A randomized trial of high-dose chemotherapy (HDCT) with autologous peripheral blood stem cell support (asct) compared to standard chemo therapy (ct) in women with metastatic breast cancer: a National Cancer Institute of Canada (NCIC) clinical trials group study. European Journal of Cancer. 37. S285–S285. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact